Everything below concerns neurotrophic signaling. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-05-25. Numbers and descriptions here follow the published literature rather than marketing material.
Semax binds to melanocortin receptors and is thought to influence neuronal survival and plasticity rather than to act through the adrenal axis. Laboratory work has shown increased expression of brain-derived neurotrophic factor and nerve growth factor in treated tissue. Changes in c-Fos, a marker of neuronal activation, have also been reported. Because the peptide is rapidly degraded by peptidases, its effects are generally attributed to downstream signaling cascades rather than to sustained receptor occupancy.
Published studies are dominated by animal models of stroke, ischemia, and cognitive impairment, with a smaller number of human trials conducted in Russia. Many of the human reports are small, single-center, and published in Russian-language journals, which limits independent scrutiny. Outcome measures vary between studies and often rely on clinician-rated scales rather than objective biomarkers. Systematic reviews have noted the methodological weaknesses and called for larger, preregistered trials before firm conclusions can be drawn.
Claims about enhanced focus, memory, or mood in healthy people rest mostly on anecdotal reports and community discussion rather than on controlled data. It remains unclear whether any cognitive benefit observed in patients recovering from brain injury would extend to uninjured users. Dose-response relationships, long-term safety, and interactions with other drugs are not well characterized in the peer-reviewed literature. Questions about optimal route of administration and treatment duration likewise remain open.
Published research covers ischemic stroke, traumatic brain injury, cognitive impairment, optic nerve conditions and attention-related measures. Much of the human evidence comes from small trials conducted in one country, which limits how far the results generalize. Animal models supply the larger share of the data, and effects seen in rodents do not transfer automatically to people. Reviews have noted that methodological reporting is often incomplete, making it difficult to pool results or compare treatment schedules across studies.
Pharmacokinetic accounts emphasize rapid breakdown. After intravenous dosing the intact peptide disappears from blood within minutes, and nasal delivery produces low but measurable concentrations. Metabolites rather than the parent molecule may account for part of the observed activity, although the relative contribution is unresolved. Dosing in the literature varies widely and no optimal schedule has been agreed. These gaps are regularly cited as a reason the findings have not produced broad clinical adoption beyond the original research setting.
| Property | Value | Notes |
|---|---|---|
| Appearance | White lyophilized powder | Typical for synthetic peptides |
| Solubility | Freely soluble in water | Also soluble in saline |
| Storage temperature | -20 C or below | Protect from repeated freeze-thaw |
| Analytical method | Reverse-phase HPLC | Confirms purity and identity |
| Common synonym | ACTH(4-10) analog | Reflects structural origin |
The mechanisms attributed to semax are inferred from animal and cell studies rather than traced to one confirmed target. The most frequently cited pathway involves increased expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal and cortical tissue. Some work points to engagement of melanocortin receptors, particularly MC4, which the parent ACTH fragment can activate. Effects on dopaminergic and serotonergic signalling have also been reported. No single account explains all observed results, and the relative weight of each pathway remains unsettled.
Published studies examine a fairly narrow set of endpoints. Rodent experiments commonly measure maze learning, infarct volume after induced ischemia, and tissue levels of neurotrophic factors. Clinical reports from Russian centres describe attention, memory and recovery scores in patients after stroke or transient ischemic attack. Most of those human studies are small and few have been repeated by independent groups. Outcome measures differ between studies, which limits direct comparison.
Circulation time for the peptide is short because peptidases cleave it readily. The Pro-Gly-Pro tail is thought to slow breakdown compared with the bare ACTH fragment, but the gain appears modest. Absorption after intranasal dosing is limited, and only a fraction of a dose is expected to reach the central nervous system. Laboratory concentrations therefore sit well above levels achieved systemically, a gap that complicates translation from bench findings to clinical claims.
Eyes: Chronic conjunctivitis, scars on cornea, corneal opacities, early cataracts Respiratory tracts: Obstructive and/or restrictive disease, pulmonary fibrosis, aggravation of tuberculosis and chronic bronchitis Neurological system: Impairment of memory, finer motor skills, numbness, etc. Psychological problems: Post traumatic stress disorder (PTSD) Children's health: Peri- and neonatal death rates increased. Failure to grow, intellectual impairment, etc. Missing or insufficient fields for research are female reproduction, chromosomal aberrations, cancer, immune deficiency, neurological sequelae, post traumatic stress disorder (PTSD) and children born after the disaster. Late cases that might never be highlighted are respiratory insufficiency, cardiac insufficiency (cor pulmonale), cancer and tuberculosis. Bhopal now has high rates of birth defects and records a miscarriage rate 7x higher than the national average. A 2014 report in Mother Jones quotes a "spokesperson for the Bhopal Medical Appeal, which runs free health clinics for survivors" as saying "An estimated 120,000 to 150,000 survivors still struggle with serious medical conditions including nerve damage, growth problems, gynaecological disorders, respiratory issues, birth defects, and elevated rates of cancer and tuberculosis."
A number of protease inhibitors are being developed targeting 3CLpro and homologous 3Cpro, including CLpro-1, GC376, AG7404, lufotrelvir, nirmatrelvir, ratutrelvir, rupintrivir. The intravenous administered prodrug PF-07304814 (lufotrelvir) entered clinical trials in September 2020. After clinical trials, in December 2021, the oral medication nirmatrelvir (formerly PF-07321332) became commercially available under emergency use authorizations (EUA), as part of the nirmatrelvir/ritonavir combination therapy (brand name Paxlovid). In May 2023, the medication got full FDA approval for high-risk adults, while children 12–18 were still covered under the EUA. The 3C-like protease inhibitor ensitrelvir received authorization to treat COVID-19 in Japan in 2022. In 2022, an ultralarge virtual screening campaign of 235 million molecules was able to identify a novel broad-spectrum inhibitor targeting the main protease of several coronaviruses. It is unusually not a peptidomimetic.
The gram-positive bacteria and cyanobacteria that would later give rise to mitochondria and chloroplast found in eukaryotic cells retained the E1 subunits that are genetically related to those found in the BCOADH enzymes.
Protein L was first isolated from the surface of bacterial species Peptostreptococcus magnus and was found to bind immunoglobulins through L chain interaction, from which the name was suggested. It consists of 719 amino acid residues. The molecular weight of protein L purified from the cell walls of Peptostreptoccus magnus was first estimated as 95kD by SDS-PAGE in the presence of reducing agent 2-mercaptoethanol, while the molecular weight was determined to 76kD by gel chromatography in the presence of 6 M guanidine HCl. Protein L does not contain any interchain disulfide loops, nor does it consist of disulfide-linked subunits. It is an acidic molecule with a pI of 4.0. Unlike protein A and protein G, which bind to the Fc region of immunoglobulins (antibodies), protein L binds antibodies through light chain interactions. Since no part of the heavy chain is involved in the binding interaction, Protein L binds a wider range of antibody classes than protein A or G. Protein L binds to representatives of all antibody classes, including IgG, IgM, IgA, IgE and IgD. Single chain variable fragments (scFv) and Fab fragments also bind to protein L. Despite this wide binding range, protein L is not a universal antibody-binding protein. Protein L binding is restricted to those antibodies that contain kappa light chains. In humans and mice, most antibody molecules contain kappa (κ) light chains and the remainder have lambda (λ) light chains. Protein L is only effective in binding certain subtypes of kappa light chains.
Sources: en.wikipedia.org
=== Carbon methylation === Radical SAM methylases/methyltransferases are one of the largest yet diverse subgroups and are capable of methylating a broad range of unreactive carbon and phosphorus centers. These enzymes are divided into three classes (Class A, B and C) with representative methylation mechanisms. The shared characteristic is the usage of SAM, split into two distinct roles: one as a source of a methyl group donor, and the second as a source of 5'-dAdo radical. Another class has been proposed (class D) but proved to be wrongly assigned.
Higher pressure than CCC (typical operation pressures of 40–160 bar vs 5–25 bar) As the pressure drops on the LiLiChro's rotor with the new cells is less than 10bar, this disadvantage has been overcome by the technology and the all-new rotary union seals will last for years of continuous use. Rotary seal wear over time
The electronic structure of superconducting cuprates is highly anisotropic. Therefore, the Fermi surface of HTS is close to the Fermi surface of the doped CuO2 plane (or multi-planes, in case of multi-layer cuprates) and can be presented on the 2‑D reciprocal space (or momentum space) of the CuO2 lattice. The typical Fermi surface within the first CuO2 Brillouin zone is sketched in Figure 1 (left). It can be derived from the band structure calculations or measured by angle resolved photoemission spectroscopy (ARPES). Figure 1 shows the Fermi surface of BSCCO measured by ARPES. In a wide range of charge carrier concentration (doping level), in which the hole-doped HTS are superconducting, the Fermi surface is hole-like (i.e. open, as shown in Figure 1). This results in an inherent in-plane anisotropy of the electronic properties of HTS. The structure of superconductor cuprates are often closely related to that of perovskites. Their structure has been described as a distorted, oxygen deficient, multi-layered, perovskite structure. One of the crystal structure properties of oxide superconductors is an alternating multi-layer of CuO2 planes with superconductivity between these layers. The more layers of CuO2, the higher Tc. This structure causes a large anisotropy in normal conducting and superconducting properties, since electrical currents are carried by holes induced in the oxygen sites of the CuO2 sheets. The electrical conduction features a much higher conductivity parallel to the CuO2 plane than in the perpendicular direction.
Sources: en.wikipedia.org
=== Imidazole antifungals === Only a few imidazole antifungals are effective against seborrheic dermatitis. Ketoconazole was found to be the most active against Pityrosporum ovale. It is available in both oral and topical formulations. It is also available as cream, gel and tablet. Unlike other drugs, it does not cause skin irritation or phototoxicity. Clotrimazole is also used in treating seborrhoea.
=== Pregnancy === The evaluation of individuals with valvular heart disease who are or wish to become pregnant is a difficult issue. Issues that have to be addressed include the risks during pregnancy to the mother and the developing fetus by the presence of maternal valvular heart disease as a pre-existing disease in pregnancy. Normal physiological changes during pregnancy require, on average, a 50% increase in circulating blood volume that is accompanied by an increase in cardiac output that usually peaks between the midportion of the second and third trimesters. The increased cardiac output is due to an increase in the stroke volume, and a small increase in heart rate, averaging 10 to 20 beats per minute. Additionally uterine circulation and endogenous hormones cause systemic vascular resistance to decrease and a disproportionately lowering of diastolic blood pressure causes a wide pulse pressure. Inferior vena caval obstruction from a gravid uterus in the supine position can result in an abrupt decrease in cardiac preload, which leads to hypotension with weakness and lightheadedness. During labor and delivery cardiac output increases more in part due to the associated anxiety and pain, as well as due to uterine contractions which will cause an increase in systolic and diastolic blood pressure. Valvular heart lesions associated with high maternal and fetal risk during pregnancy include:
== Clinical Relevance == Despite normally being a commensal organism, C. xerosis has been linked to many different opportunistic infections in humans and animals, including endocarditis, sepsis, abscesses, and osteomyelitis. However, it is possible that many early reports of this bacterium may have been cases of misidentification: a 1996 study found that out of 25 clinical isolates originally identified as C. xerosis, all were actually Corynebacterium amycolatum based on a number of biochemical tests which came back as different from the C. xerosis reference strain. Similarly, there is also evidence that some infections attributed to C. xerosis may have been caused by Corynebacterium striatum. Therefore, it is difficult to determine the actual extent of C. xerosis infections as reported in historic literature; however, modern sequencing and phenotypic analyses have allowed for more accurate identification of C. xerosis in clinical infections.
== Performing with the Grateful Dead == In early 1970, Lagin initiated a correspondence with Jerry Garcia after seeing the Grateful Dead at the Boston Tea Party in 1969. In May 1970, he helped facilitate a concert and free live outdoor performance featuring the band at MIT that coincided with the Kent State shootings. That summer, Lagin, at Garcia's invitation, visited San Francisco and contributed piano to "Candyman" during the American Beauty album sessions, played in several jams, and started what would become close friendships with Garcia, bassist Phil Lesh, and David Crosby. From 1970 to 1975, Lagin contributed Hammond B3 organ, electric piano, and clavichord to material of his choice (primarily—but not exclusively—songs with long instrumental passages) at several Grateful Dead concerts. His first performances with the Grateful Dead were on November 5 and November 8, 1970 at the Capitol Theater in Port Chester, New York; his first complete concert was at Boston University's Sargent Gym on November 21, 1970. During many 1974 Grateful Dead concerts over several tours, including Europe, he performed a middle set of electronic music, including parts of his composition Seastones, on computer-controlled analog synthesizers with Phil Lesh on electronically processed bass. Some sets included Jerry Garcia playing guitar filtered through effects processors and Bill Kreutzmann on drums; these sets occasionally segued into the final Grateful Dead set, with Lagin performing with the Dead, including an appearance in The Grateful Dead Movie.
Sources: en.wikipedia.org
It is associated with the melanocortin receptor family, particularly subtypes found in the central nervous system. This interaction is separate from the adrenal pathway activated by full-length ACTH.
Peptidases degrade the compound within minutes in circulation. This short half-life is one reason nasal delivery is used, placing the substance close to the olfactory and trigeminal pathways.
No large multicenter trials have been published in English-language journals. The existing human evidence consists mainly of smaller studies conducted in Russia, which limits generalization.
The main proposal is modulation of neurotrophic factors such as brain-derived neurotrophic factor, supported largely by animal experiments. Receptor-level targets have not been firmly established. Most reviews describe the mechanism as only partially characterized.